BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren X, Chen JF. Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms. Front Neurosci 2020;14:602697. [PMID: 33390888 DOI: 10.3389/fnins.2020.602697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu G, Zhang S, Zheng L, Hu Z, Cheng L, Chen L, Li J, Shi Z. In silico identification of A1 agonists and A2a inhibitors in pain based on molecular docking strategies and dynamics simulations. Purinergic Signal 2021. [PMID: 34677752 DOI: 10.1007/s11302-021-09808-4] [Reference Citation Analysis]
2 Holanda VAD, Didonet JJ, Costa MBB, do Nascimento Rangel AH, da Silva ED Jr, Gavioli EC. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals (Basel) 2021;14:775. [PMID: 34451872 DOI: 10.3390/ph14080775] [Reference Citation Analysis]
3 Anis E, Xie A, Brundin L, Brundin P. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease. Trends Endocrinol Metab 2021:S1043-2760(21)00268-X. [PMID: 34949514 DOI: 10.1016/j.tem.2021.11.005] [Reference Citation Analysis]
4 . Selected Literature Watch. Journal of Caffeine and Adenosine Research 2021;11:23-4. [DOI: 10.1089/caff.2021.29019.slw] [Reference Citation Analysis]
5 Reichmann H. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease]. Fortschr Neurol Psychiatr 2022. [PMID: 35584767 DOI: 10.1055/a-1785-3632] [Reference Citation Analysis]
6 Shang P, Baker M, Banks S, Hong SI, Choi DS. Emerging Nondopaminergic Medications for Parkinson's Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists. J Mov Disord 2021;14:193-203. [PMID: 34399565 DOI: 10.14802/jmd.21035] [Reference Citation Analysis]
7 Kanno H, Handa K, Murakami T, Aizawa T, Ozawa H. Chaperone-Mediated Autophagy in Neurodegenerative Diseases and Acute Neurological Insults in the Central Nervous System. Cells 2022;11:1205. [DOI: 10.3390/cells11071205] [Reference Citation Analysis]
8 Huang L, Sperlágh B. Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms. Curr Opin Pharmacol 2021;61:106-13. [PMID: 34688994 DOI: 10.1016/j.coph.2021.09.003] [Reference Citation Analysis]
9 Tabolacci C, Cordella M, Rossi S, Bonaccio M, Eramo A, Mischiati C, Beninati S, Iacoviello L, Facchiano A, Facchiano F. Targeting Melanoma-Initiating Cells by Caffeine: In Silico and In Vitro Approaches. Molecules 2021;26:3619. [PMID: 34199192 DOI: 10.3390/molecules26123619] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Barrea L, Pugliese G, Frias-Toral E, El Ghoch M, Castellucci B, Chapela SP, Carignano MLA, Laudisio D, Savastano S, Colao A, Muscogiuri G. Coffee consumption, health benefits and side effects: a narrative review and update for dietitians and nutritionists. Crit Rev Food Sci Nutr 2021;:1-24. [PMID: 34455881 DOI: 10.1080/10408398.2021.1963207] [Reference Citation Analysis]
11 Behl T, Madaan P, Sehgal A, Singh S, Sharma N, Bhatia S, Al-Harrasi A, Chigurupati S, Alrashdi I, Bungau SG. Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target. Int J Mol Sci 2021;22:10161. [PMID: 34576325 DOI: 10.3390/ijms221810161] [Reference Citation Analysis]
12 Kovacs G, Reimer L, Jensen PH. Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies. Front Neurol 2021;12:742625. [PMID: 34744980 DOI: 10.3389/fneur.2021.742625] [Reference Citation Analysis]
13 Behl T, Madaan P, Sehgal A, Singh S, Anwer MK, Makeen HA, Albratty M, Mohan S, Bungau S. Mechanistic Insights Expatiating the Redox-Active-Metal-Mediated Neuronal Degeneration in Parkinson's Disease. Int J Mol Sci 2022;23:678. [PMID: 35054862 DOI: 10.3390/ijms23020678] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
14 Di Rocco M, Galosi S, Lanza E, Tosato F, Caprini D, Folli V, Friedman J, Bocchinfuso G, Martire A, Di Schiavi E, Leuzzi V, Martinelli S. Caenorhabditis elegans provides an efficient drug screening platform for GNAO1-related disorders and highlights the potential role of caffeine in controlling dyskinesia. Hum Mol Genet 2021:ddab296. [PMID: 34622282 DOI: 10.1093/hmg/ddab296] [Reference Citation Analysis]
15 Miao Y, Chen X, You F, Jia M, Li T, Tang P, Shi R, Hu S, Zhang L, Chen JF, Gao Y. Adenosine A2A receptor modulates microglia-mediated synaptic pruning of the retinogeniculate pathway during postnatal development. Neuropharmacology 2021;200:108806. [PMID: 34562441 DOI: 10.1016/j.neuropharm.2021.108806] [Reference Citation Analysis]